Two million patients have received the CYPHER sirolimus-eluting coronary stent since its market introduction in Europe in April 2002, a first-time milestone for any company in the drug- eluting stent industry. The CYPHER stent is the world leading drug-eluting stent for the treatment of coronary artery disease and helped redefine innovation in interventional cardiology. Yahoo News (http://biz.yahoo.com/prnews/060426/nyw101.html?.v=48)
Simplifying Global Compliance
Recommended Products
EU MDR Compliance: A Checklist for Meeting Manufacturing, Safety and Performance Requirements
The FDAnews report EU MDR Compliance can help. Our editors have combed through the regulations, picking out the most minute compliance points and building them into a checklist of 200+ requirements you can use to confirm that you are satisfying all the EU mandates for device manufacturing.
Accelerating Generic Drug Development: The FDA’s New Plan for Increasing Generic Competition
Accelerating Generic Drug Development explains the FDA’s new policy and shows how to navigate the new pathway to approval.
Editor's Picks
Devicemakers Pay $9.5 Million for Selling Uncleared Products
The FDA hit Instrumed with a warning letter in 2014.
Federal Circuit Won’t Rehear Purdue Pharma’s OxyContin Patent Claims
The U.S. Court of Appeals for the Federal Circuit turned down Purdue’s appeal and upheld the PTAB ruling.
